title: Topical pimecrolimus lacks genotoxicity and cytotoxicity by means of micronucleus erythrocyte rodent assay.
abstract: Topical pimecrolimus is an alternative treatment of atopic dermatitis. However, rare cases of malignancy have been reported with their use. This study was performed to investigate the possible geno- or cytotoxic effect in mouse bone marrow caused by systemic absorption of pimecrolimus 1% cream. In order to determine this, induction of micronucleated erythrocytes (MNE) in mouse peripheral blood was determined after the cutaneous application of three different doses, daily for 5 consecutive days. No differences were found in frequencies of polychromatic erythrocytes, MNE, and micronucleated polychromatic erythrocytes in the different groups of study. In conclusion, under described conditions, no geno- or cytotoxic effects were detected after the cutaneous application of pimecrolimus.
authors.affiliation: Laboratorio de Inmunobiología Molecular, Facultad de Medicina, Universidad Autónoma de Nayarit, Tepic, México.
authors.forename: Aurelio
authors.initials: A
authors.lastname: Flores-García
authors.forename: Belinda C
authors.initials: BC
authors.lastname: Gómez-Meda
authors.forename: Ana L
authors.initials: AL
authors.lastname: Zamora-Pérez
authors.forename: Vicente
authors.initials: V
authors.lastname: Garibaldi-Becerra
authors.forename: Martha
authors.initials: M
authors.lastname: Barba-Barajas
authors.forename: Guillermo M
authors.initials: GM
authors.lastname: Zúñiga-González
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects* / Q000473:pathology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D048629:Micronuclei, Chromosome-Defective / Q000139:chemically induced*; D015162:Micronucleus Tests; D009824:Ointments; D012867:Skin / Q000378:metabolism; D012869:Skin Absorption; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity
chemical_list: D007166:Immunosuppressive Agents; D009824:Ointments; C117268:pimecrolimus; D016559:Tacrolimus